Downstream bioprocessing 2022

Addressing current challenges in lentiviral vector purification & associated analytics

Cell & Gene Therapy Insights 2022; 8(9), 1589–1599

DOI: 10.18609/cgti.2022.231

Published: 16 January 2023
Innovator Insight
Bryan Zee, Anindya Dasgupta

Charlotte Barker, Editor, BioInsightstalks to Bryan Zee, Associate scientist, Juno Therapeutics and Anindya Dasgupta, Director of GMP, EXPRESSION Therapeutics

Bryan Zee started his purification career at Amgen’s PD group where he developed several clinical stage biologics and handled a myriad of modalities such as mAbs, bispecifics, and Fc-fusion proteins. Since 2019 he’s been at BMS’s viral vector PD department where he has developed BMS’s LVV purification platform and AAV purification platform.

Anindya Dasgupta is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina, USA. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta, USA, were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of Υδ T cells in serum free media . Anindya is a co-inventor of a patent on anti-cancer strategy. At his recent role at Cincinnati Children’s Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.